FDA Approves First Treatment for Acid Sphingomyelinase Deficiency, a Rare Genetic Disease

資源中心分類:Global Express
文章標籤:

 

The U.S. Food and Drug Administration approved Xenpozyme (Olipudase alfa) for intravenous infusion in pediatric and adult patients with Acid Sphingomyelinase Deficiency (ASMD), a rare genetic disease that causes premature death. Xenpozyme is the first approved medication to treat symptoms that are not related to the central nervous system in patients with ASMD.